Tiziana Life Sciences Ltd (NASDAQ:TLSA) Sees Large Decline in Short Interest

Tiziana Life Sciences Ltd (NASDAQ:TLSA) was the recipient of a large decline in short interest in December. As of December 15th, there was short interest totalling 170,100 shares, a decline of 18.3% from the November 30th total of 208,100 shares. Based on an average daily trading volume, of 306,000 shares, the short-interest ratio is currently 0.6 days. Approximately 0.2% of the company’s stock are sold short.

Tiziana Life Sciences Stock Performance

Shares of TLSA traded down $0.03 during mid-day trading on Friday, reaching $0.67. The company had a trading volume of 788,226 shares, compared to its average volume of 227,787. Tiziana Life Sciences has a 52 week low of $0.41 and a 52 week high of $1.74. The firm has a 50-day moving average price of $0.93 and a 200 day moving average price of $0.95.

Institutional Investors Weigh In On Tiziana Life Sciences

A hedge fund recently raised its stake in Tiziana Life Sciences stock. Zhang Financial LLC boosted its holdings in shares of Tiziana Life Sciences Ltd (NASDAQ:TLSA) by 24.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 69,387 shares of the company’s stock after buying an additional 13,500 shares during the quarter. Zhang Financial LLC owned approximately 0.07% of Tiziana Life Sciences worth $67,000 at the end of the most recent quarter.

Tiziana Life Sciences Company Profile

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.